201 related articles for article (PubMed ID: 31131495)
1. PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target.
Bertucci F; Finetti P; Monneur A; Perrot D; Chevreau C; Le Cesne A; Blay JY; Mir O; Birnbaum D
Mol Oncol; 2019 Jul; 13(7):1577-1588. PubMed ID: 31131495
[TBL] [Abstract][Full Text] [Related]
2. The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma.
Bertucci F; De Nonneville A; Finetti P; Perrot D; Nilbert M; Italiano A; Le Cesne A; Skubitz KM; Blay JY; Birnbaum D
Ann Oncol; 2018 Feb; 29(2):459-465. PubMed ID: 29069276
[TBL] [Abstract][Full Text] [Related]
3. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
[No Abstract] [Full Text] [Related]
4. Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature.
Bertucci F; Niziers V; de Nonneville A; Finetti P; Mescam L; Mir O; Italiano A; Le Cesne A; Blay JY; Ceccarelli M; Bedognetti D; Birnbaum D; Mamessier E
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017155
[TBL] [Abstract][Full Text] [Related]
5. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas.
Bertucci F; Finetti P; Perrot D; Leroux A; Collin F; Le Cesne A; Coindre JM; Blay JY; Birnbaum D; Mamessier E
Oncoimmunology; 2017; 6(3):e1278100. PubMed ID: 28405501
[TBL] [Abstract][Full Text] [Related]
6. Individual and Combined Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients.
Kim KM; Moon YJ; Park SH; Park HJ; Wang SI; Park HS; Lee H; Kwon KS; Moon WS; Lee DG; Kim JR; Jang KY
PLoS One; 2016; 11(9):e0163193. PubMed ID: 27643881
[TBL] [Abstract][Full Text] [Related]
7. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
Pignochino Y; Capozzi F; D'Ambrosio L; Dell'Aglio C; Basiricò M; Canta M; Lorenzato A; Vignolo Lutati F; Aliberti S; Palesandro E; Boccone P; Galizia D; Miano S; Chiabotto G; Napione L; Gammaitoni L; Sangiolo D; Benassi MS; Pasini B; Chiorino G; Aglietta M; Grignani G
Mol Cancer; 2017 Apr; 16(1):86. PubMed ID: 28454547
[TBL] [Abstract][Full Text] [Related]
8. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
9. Nuclear PARP1 expression and its prognostic significance in breast cancer patients.
Mazzotta A; Partipilo G; De Summa S; Giotta F; Simone G; Mangia A
Tumour Biol; 2016 May; 37(5):6143-53. PubMed ID: 26614429
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis.
Gonçalves A; Finetti P; Sabatier R; Gilabert M; Adelaide J; Borg JP; Chaffanet M; Viens P; Birnbaum D; Bertucci F
Breast Cancer Res Treat; 2011 May; 127(1):273-81. PubMed ID: 21069454
[TBL] [Abstract][Full Text] [Related]
11. Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes.
Diamantopoulos P; Zervakis K; Zervakis P; Sofotasiou M; Vassilakopoulos T; Kotsianidis I; Symeonidis A; Pappa V; Galanopoulos A; Solomou E; Kodandreopoulou E; Papadopoulou V; Korkolopoulou P; Mantzourani M; Kyriakakis G; Viniou NA
Blood Cancer J; 2017 Feb; 7(2):e533. PubMed ID: 28212373
[TBL] [Abstract][Full Text] [Related]
12. PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
Murnyák B; Kouhsari MC; Hershkovitch R; Kálmán B; Marko-Varga G; Klekner Á; Hortobágyi T
Oncotarget; 2017 Jul; 8(28):46348-46362. PubMed ID: 28654422
[TBL] [Abstract][Full Text] [Related]
13. PARP1 is a novel independent prognostic factor for the poor prognosis of chordoma.
Li Z; Lv T; Liu Y; Huang X; Qiu Z; Li J
Cancer Biomark; 2016 Mar; 16(4):633-9. PubMed ID: 27002766
[TBL] [Abstract][Full Text] [Related]
14. Up-Regulation of PARP1 Expression Significantly Correlated with Poor Survival in Mucosal Melanomas.
Donizy P; Wu CL; Mull J; Fujimoto M; Chłopik A; Peng Y; Shalin SC; Selim MA; Puig S; Fernandez-Figueras MT; Shea CR; Biernat W; Ryś J; Marszalek A; Hoang MP
Cells; 2020 May; 9(5):. PubMed ID: 32380691
[TBL] [Abstract][Full Text] [Related]
15. PARP1: A potential biomarker for gastric cancer.
Afzal H; Yousaf S; Rahman F; Ahmed MW; Akram Z; Akhtar Kayani M; Mahjabeen I
Pathol Res Pract; 2019 Aug; 215(8):152472. PubMed ID: 31174925
[TBL] [Abstract][Full Text] [Related]
16. Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors?
Mangoni M; Sottili M; Salvatore G; Campanacci D; Scoccianti G; Beltrami G; Delli Paoli C; Dominici L; Maragna V; Olmetto E; Meattini I; Desideri I; Bonomo P; Greto D; Livi L
Radiol Med; 2019 Apr; 124(4):282-289. PubMed ID: 29582320
[TBL] [Abstract][Full Text] [Related]
17. Biological and clinical significance of PARP1 protein expression in breast cancer.
Green AR; Caracappa D; Benhasouna AA; Alshareeda A; Nolan CC; Macmillan RD; Madhusudan S; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Jan; 149(2):353-62. PubMed ID: 25528020
[TBL] [Abstract][Full Text] [Related]
18. PARP1 as a Marker of an Aggressive Clinical Phenotype in Cutaneous Melanoma-A Clinical and an In Vitro Study.
Kupczyk P; Simiczyjew A; Marczuk J; Dratkiewicz E; Beberok A; Rok J; Pieniazek M; Biecek P; Nevozhay D; Slowikowski B; Chodaczek G; Wrzesniok D; Nowak D; Donizy P
Cells; 2021 Jan; 10(2):. PubMed ID: 33572647
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome.
Diamantopoulos PT; Kontandreopoulou CN; Symeonidis A; Kotsianidis I; Pappa V; Galanopoulos A; Vassilakopoulos T; Dimou M; Solomou E; Kyrtsonis MC; Siakantaris M; Angelopoulou M; Kourakli A; Papageorgiou S; Christopoulou G; Roumelioti M; Panayiotidis P; Viniou NA;
Ann Hematol; 2019 Jun; 98(6):1383-1392. PubMed ID: 30877373
[TBL] [Abstract][Full Text] [Related]
20. Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas.
Le Guellec S; Lesluyes T; Sarot E; Valle C; Filleron T; Rochaix P; Valentin T; Pérot G; Coindre JM; Chibon F
Ann Oncol; 2018 Aug; 29(8):1828-1835. PubMed ID: 29860427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
